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Capsule summary: We report a case of autoinflammation caused by a heterozygous variant 
in TNFAIP3 manifesting as progressive neuroinflammation. Mutant A20 protein failed to 
control interferon-dependent transcription. We demonstrate excellent therapeutic response to 
Janus kinase inhibition.    
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To the editor, 
Heterozygous loss-of-function pathogenic variants in Tumour-Necrosis-Factor-Alpha-
Induced-Protein-3 gene (TNFAIP3) cause autoinflammation due to haploinsufficiency of A20 
protein (HA20). HA20 commonly manifests as severe orogenital ulceration and uveitis (1). 
Central nervous system (CNS) inflammation is rare, but is reported in HA20; and animal 
studies have illustrated that mice with mutant TNFAIP3  are prone to severe 
neuroinflammation (2, 3). Loss of A20 function causes spontaneous cerebral inflammation, as 
demonstrated by robust microglial activation, reactive astrogliosis, endothelial activation, 
increased oxidative/nitrosative stress and expression of NFκB regulated pro-inflammatory 
soluble mediators such as IL-1β, TNF, IL-6 and MCP-1 in the brain (3). CNS involvement as 
the sole clinical manifestation of heterozygous TNFAIP3 variants in humans has never been 
described. We report a case of TNFAIP3 mediated autoinflammation manifesting as 
progressive neuroinflammation. We show that mutated A20 protein failed to control 
interferon (IFN)-dependent transcription, highlighting an entirely novel mechanism of 
autoinflammation in HA20. Targeted treatment with the Janus kinase inhibitor (JAKI) 
baricitinib led to marked clinical, radiological and immunological improvement.  Methods 
are provided online.  
The proband (III.1) was an 8 year-old female of non-consanguineous Pakistani-Indian 
descent (Fig1A) who presented with left-sided focal seizures and hemiparesis, uveitis and 
congitive decline. She had choreoretinitis from the age of 6-months, considered secondary to 
congenital infection; no pathogen had been identified, however. There was no history of 
systemic symptoms; she had occasional mouth ulcers, but no genital ulcers. Magnetic 
resonance imaging (MRI) of her brain revealed contrast-enhancing T2-hypointense 
intracranial mass lesions, affecting predominantly the grey matter of the paracentral lobule 
and of the thalamus on the left, with surrounding oedema (Fig1B-E). Laboratory tests 
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included: negative autoantibody screen; and negative/normal: complement function studies; 
targeted NOD2 genetic testing; nitroblue tetrazolium test; immunoglobulin levels, 
lymphocyte subsets and CSF analysis (supplemental table 1). She had modestly elevated 
erythrocyte sedimentation rate (ESR) of 25 mm/h (normal range< 5mm/h); and normal C-
reactive-protein (CRP, 5 mg/L, normal range< 5mg/L). Brain histology revealed 
granulomatous inflammation, focal necrosis, and calcification (Fig1F). Tuberculosis (TB) 
was still considered a possible differential diagnosis, and empirical anti-TB treatment was 
started (isoniazid/rifampicin/pyrazinamide/moxifloxacin). Brain tissue culture, PCR-testing 
for mycobacteria, and Quantiferon test were all negative, however. There was progression of 
the mass lesion, worsening of left-sided hemiplegia, and new onset ataxia. At that point, she 
was considered to have an unclassified granulomatous neuroinflammatory disorder, 
reminiscent of neurosarcoid. Based on that, she received treatment with prednisolone 2 
mg/kg/day, weaning to 0.5 mg/kg/day over 6 months; and mycophenolate mofetil (1200 
mg/m2/day). There was no response to this treatment, with further increase in size of the brain 
lesion. Intravenous cyclophosphamide (6 doses, 500-750 mg/m2) was then given, and 
prednisolone continued at a higher dose (2 mg/kg/day). There was poor response to these 
treatments and significant steroid related side effects noted (weight gain, Cushingoid 
appearance, and arterial hypertension). A second brain biopsy again revealed necrotising 
granulomatous inflammation, and no evidence of infection. Whole-body PET-CT revealed no 
evidence of malignancy; brain-CT revealed intracerebral calcification (Fig1G). In view of the 
significant development of intracerebral calcification, she was considered to have an 
unclassified interferonopathy and was started on baricitinib (6 mg/day), an oral JAK1/JAK2 
inhibitor that blocks IFN signalling (via a programme sponsored by Eli Lilly and Company). 
This resulted in rapid clinical and radiological improvement: 24 months later she remains 
stable with no further seizures and marked resolution of the intracerebral inflammatory lesion 
(Fig1H-J). Prednisolone was weaned off for the first time in 2 years. Her younger sister 
(III.2) suffered from arthritis, and a facial malar type rash from the age of 6 months old.  II.4 
had died at the age of 17 years, from early-onset systemic lupus erythematosus. II-2 had mild 
oral ulceration.  
Whole exome sequencing (WES) revealed a heterozygous c.A1939C (NM_001270508) 
p.T647P variant in TNFAIP3, confirmed with Sanger sequencing in III-1, also present in the 
symptomatic sibling (III-2), and mildly symptomatic mother (II-2; Fig1A and K). This 
variant resides in the fourth zinc finger (Znf4) domain of A20, an area that has E3 ubiquitin 
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ligase activity and is involved in recruiting adaptor proteins, such as Tax-1-binding-protein-1 
(TAX1BP1) and the A20-binding-inhibitor of NF-κB (ABIN-1), to enable A20 to exert its 
inhibitory function (4).  
PBMCs derived from heterozygotes for the p.T647P TNFAIP3 showed increased expression 
of NF-κB phosphorylated p65 transcription factor compared to control cells, p=0.0124 
(Fig1L). Similar differences were also observed in Human dermal fibroblast cells (HDFC) 
from III-1 compared to control HDFC, p=0.0001 (Fig1M), suggesting that the heterozygous 
p.T647P TNFAIP3 variant impaired the ability of the A20 to regulate the canonical NF-κB 
pathway.  TNF-stimulated HDFC from III-1 also showed increased molecular weight of 
Lys63-ubiquitinated NF-kappa-B essential modulator (NEMO) as a result of insufficient A20 
deubiquitinase activity. (Fig1N). 
Activated NF-κB subunits are known to promote the transcription of genes encoding 
proinflammatory cytokines (5). Levels of several proinflammatory cytokines were 
substantially higher in heterozygotes for p.T647P TNFAIP3 compared to healthy controls: IL-
1β (p=0.02), IL-6 (p=0.02), IL-8 (p=0.02) and TNF-α (p=0.02).  
Recent studies suggest that A20 functions as a negative regulator of the NLRP3 
inflammasome independently of its role in NF-κB regulation (1). Consistent with these data, 
PBMC from III-1 showed constitutive activation of the NLRP3 inflammasome, which 
resulted in activation of caspase-1 (p=0.009) and increased secretion of active IL-1β 
(p=0.007) and IL-18 (p=0.01); supplemental figure 1. 
Activation of the interferon regulatory factor-3 (IRF-3), a critical transcription factor that 
regulates Interferon (IFN) immune responses, is negatively regulated by A20 through 
interaction with the NF-κB-activating kinase/Traf family member-associated NF-κB 
activator-binding kinase 1 (TBK1) (6). We thus next examined if IFN immune responses 
were impaired. Type-1 IFN stimulated gene expression levels were upregulated in whole 
blood from III-1 (Fig2A); serum IFN-α and IFN- β were also elevated compared to controls 
(p=0.04 and p=0.049 respectively). We also observed enhanced expression of phosphorylated 
IRF-3 in lymphocytes from all heterozygotes for p.T647P TNFAIP3 variants (p=0.0007, 
Fig2B), and in HDFC from III-1 compared to control, p=0.009 (Fig2C).  Lymphocytes from 
III-1 also demonstrated increased phosphorylation of STAT-1 and STAT-3 compared to 
control, p=0.0001 and p=0.0001 respectively; similar differences in STAT-1 and STAT-3 
were observed in HDFC (Fig2D-E and supplemental figure 2 A-B).    
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siRNA mediated silencing of TNFAIP3 in HDFC resulted in upregulation  of phosphorylated 
p65 (p=0.04), phosphorylated IRF-3 (p=0.0043), phosphorylated STAT-1 (p=0.037), and 
phosphorylated STAT-3 (p=0.03) expression compared to scrambled siRNA control cells 
(supplemental Fig2C-G).   
We documented almost complete clinical and radiological resolution of neuroinflammation in 
III-1 (Fig1H-J), and normalisation of IFN-induced gene expression in whole blood (Fig2F) 
following treatment with baricitinib.  
To establish whether the loss of A20 negative regulatory control over IRF-3 activation was 
secondary to the reduced binding capacity of the A20 protein to TBK1, we next employed a 
co-immunoprecipitation assay. In HDFC from III-1, there was no significant upregulation in 
binding of TBK1 to the A20 protein in response to TNFα, in contrast to significantly 
increased binding of A20/TBK1 observed in control cells (Fig2G-H).  
We next examined whether IFN-mediated immune responses might be generally dysregulated 
in HA20, irrespective of neurological involvement, in a 4 year-old non-consanguineous 
Caucasian male  with HA20, without any neurological involvement (Fig2I). He presented 
with recurrent oral inflammation and penile ulceration, and was heterozygous for the 
p.N98Tfs25 TNFAIP3 variant, as was his symptomatic father who suffered similar clinical 
features from early childhood. We confirmed significant upregulation of p65 (p=0.11), 
phosphorylated IRF-3 (p=0.0001; Fig2J) and STAT-1 (p=0.0013) and STAT-3 expression 
(p=0.009; Fig2K/L) in lymphocytes from this boy compared to healthy controls.  
We expand the spectrum of clinical presentation associated with HA20 caused by variants in 
TNFAIP3, which now includes progressive neuroinflammation. We provide insights into the  
mechanism for the observed immunophenotype through loss of A20-mediated negative 
regulatory control of IRF3 activation, and subsequent dysregulated IFN pathway signalling.  
TNFAIP3 mediated autoinflammation should now be considered in the differential diagnosis 
of neuroinflammation, particularly in the presence of intracerebral calcification and uveitis. 
JAK inhibition may represent a novel therapeutic approach for autoinflammation and 
neuroinflammation associated with heterozygous TNFAIP3 variants. 
Neuroinflammation is rare, but has been previously reported in HA20. In a recent case series, 
CNS vasculitis was reported in 2/16 (13%) HA20 patients. The true frequency of CNS 
involvement in HA20 may be underappreciated, however, as not all patients were 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
systematically assessed for presence of neurological involvement (2).  We therefore suggest 
that clinicians should consider screening for neuroinflammation in all patients with suspected 
HA20. Future collaborative studies may facilitate more detailed phenotype-genotype 
correlation and could help identify which HA20 patients might be more at risk of 
neuroinflammation, but currently these data do not exist. Notably, animal studies have 
previously suggested that heterozygous variants in TNFAIP3 cause milder 
neuroinflammatory changes compared to the severe neuroinflammation observed in complete 
A20 KO mice (3). The heterozygous state in our patients, therefore, may contribute to the less 
severe phenotype observed in some of our patients. Of note, immune cells from II-2 and III-
2,also heterozygotes for the p.T647P TNFAIP3 variant, exhibited enhanced NF-κB activity 
and IRF-3 activation, but these individuals currently have a much milder phenotype, further 
emphasising the previously described clinical heterogeneity of HA20 even within the same 
kindred (1,2). Additional modifying alleles, genetic and/or environmental risk factors (such 
as intercurrent infection or other triggers) may play a role in modifying the phenotype and 
influence susceptibility to, or disease severity of HA20.  
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Figure legends:  
Figure 1. Pedigree, magnetic resonance imaging (MRI) imaging features and genetic 
sequencing results. (A) Pedigree shows segregation of the p.T647P heterozygous TNF alpha 
induced protein 3 (TNFAIP3) variant. (B-C) Axial T2 weighted images at the level of the 
peri-rolandic cortex and basal ganglia shows hypointense solid areas (arrows) surrounded by 
vasogenic oedema in the right paracentral lobule (B) and thalamus (C). (D-E) Axial T1 WI 
post contrast at the same levels shows intense enhancement of the solid lesions (arrows). (F) 
Brain biopsy showed necrotising granulomatous inflammation with positive p65 nuclear 
stain. (G) Computed tomography (CT) brain scan demonstrated foci of calcifications (arrow) 
in the thalamic lesion and in the periventricular white matter within the area of vasogenic 
oedema. (H-J) Axial T2 and T1 WI post-contrast showed almost complete resolution of the 
previously noted lesions. (K) Sanger sequencing chromatogram of TNFAIP3 gene aligned to 
reference sequence exon 8. Line indicates a heterozygous TNFAIP3 p.T647P variant in III.1, 
III.2 and II-2. (L-M) There was increased expression of phosphorylated p65 in patient 
lymphocytes (p=0.0124) and patient human dermal fibroblast cells (HDFC, p=0.0001) 
compared to control cells. (N) TNF-stimulated dermal fibroblasts from III.1 showed 
increased abundance and molecular weight of Lys63- ubiquitinated NF-kappa-B essential 
modulator (NEMO).   
Figure 2. Enhanced type 1 IFN (interferon) signalling in immune cells derived from 
patients with heterozygous p.T647P variant in TNFAIP3. (A) Type 1 IFN stimulated gene 
expression levels were upregulated in whole blood from III-1 at comparable levels to that 
seen in a patient with STING vasculopathy with onset in infancy (SAVI). Control data were 
derived from n=13 individuals. (B-C) There was increased expression of phosphorylated 
IRF-3 in lymphocytes from all heterozygotes for p.T647P TNFAIP3 (p=0.0007) and in 
human dermal fibroblast cells (HDFC) from III-1 (p=0.009) compared to control cells. (D-E). 
Lymphocytes from p.T647P TNFAIP3 heterozygotes demonstrated increased STAT-1 and 
STAT-3 expression, p=0.0001. (F) Treatment with an oral JAK 1/2 inhibitor resulted in a 
significant decrease in type I IFN gene expression. (G-H) In fibroblasts derived from III-1 
there was impaired ability of the p.T647P A20 protein to bind to TBK1 in response to TNF-α.  
(I) Pedigree for family of patient with heterozygous p.N98Tfs25 TNFAIP3 associated 
autoinflammation. (J-L) There was also increased expression of phosphorylated IRF-3 
(p=0.0001), STAT-1 (p=0.0013) and STAT-3 (p=0.009) in lymphocytes derived from the 
p.N98Tfs25 TNFAIP3 heterozygote compared to control cells (p=0.0001). IRF3=interferon-
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regulatory-factor-3; STAT1 and STAT3=signal transducer and activator of transcription-1 
and 3; STING=stimulator of interferon genes; TNFAIP3= TNF alpha induced protein 3. 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
C
I
G
H
I
B EDC
F
I
J
F
J
A
K
0 10 20 30 40 50 60
0
50
100
150
200
Time (mins)
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
 o
f 
N
F
-
B
 p
h
o
s
p
h
o
ry
la
te
d
 p
6
5
 (
p
S
5
2
9
),
 i
n
 l
y
m
p
h
o
c
y
te
s
WT/WT
p.T647P TNFAIP3/WT
p=0.0124
0 10 20 30 40 50 60
0
1
2
3
4
5
Time (mins)
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
 o
f 
N
F
-
B
 p
h
o
s
p
h
o
ry
la
te
d
p
6
5
 (
p
S
5
2
9
) 
in
 H
D
F
C
WT/WT
p.T647P TNFAIP3/WT
p=<0.0001
L M N
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
0 10 20 30 40 50 60
0
5
10
15
Time (mins)
p
-I
R
F
3
 (
S
e
r3
9
6
) 
e
x
p
re
s
s
io
n
 i
n
 H
D
F
C
p.T647P TNFAIP3/WT
WT/WT
p=0.0093
A
G
B
E H
C
F
I
IF
I2
7
IF
I4
4L
IF
IT
1
IS
G
15
R
SA
D
2
SI
G
LE
C
1
0
20
40
60
80
R
e
la
ti
ve
 Q
u
a
n
ti
fi
c
a
ti
o
n
 =
 2
(-


C
q
)
III.1
WT/WT
WT/p.V155M TMEM173 (SAVI)
0 10 20 30 40 50 60
0
2
4
6
8
Time (mins)
P
-S
T
A
T
1
 e
x
p
re
s
s
io
n
 i
n
 l
y
m
p
h
o
c
y
te
s
p.T647P TNFAIP3/WT
WT/WT
p=<0.0001
0 10 20 30 40 50 60
0
2
4
6
8
10
Time (mins)
P
-S
T
A
T
3
 e
x
p
re
s
si
o
n
 i
n
 L
ym
p
h
o
cy
te
s
p.T647P TNFAIP3/WT
WT/WT
p=0.0001
0 10 20 30 40 50 60
0
50
100
150
Time (mins)
P
-I
R
F
3
 (
S
e
r3
9
6
) 
e
x
p
re
s
s
io
n
 i
n
 l
y
m
p
h
o
c
y
te
s
WT/WT
p.T647P TNFAIP3/WT
p=0.0007
IF
I2
7
IF
I4
4
L
IF
IT
1
IS
G
1
5
R
S
A
D
2
S
IG
L
E
C
1
0
2 0
4 0
6 0
8 0
In te rfe ro n  S tim u la te d  G e n e s
R
e
la
ti
v
e
 Q
u
a
n
ti
fi
c
a
ti
o
n
 =
 2
(-


C
q
)
B a s e lin e
M o n th  2
M o n th  6
H e a lth y  C o n tro l
W
T/
W
T 
W
T/
W
T+
 T
N
F-
α
W
T/
p.
T6
47
P 
TN
FA
IP
3 
W
T/
p.
T6
47
P 
TN
FA
IP
3 
+T
N
F-
α
0
20000
40000
60000
A
20
-T
B
K
1
 p
ro
te
in
 b
in
d
in
g
 
p=0.002
0 5 10 20 30 60
2.5
3.0
3.5
4.0
4.5
Time (mins)
P
-S
T
A
T
3
 e
x
p
re
s
s
io
n
 i
n
 L
y
m
p
h
o
c
y
te
s
WT/WT
p.N98Tfs25 TNFAIP3/WT
p=0.009
0 10 20 30 40 50 60
0
2
4
6
8
Time (mins)
P
-I
R
F
3
 (
S
e
r 
3
9
6
) 
e
x
p
re
s
s
io
n
 i
n
 l
y
m
p
h
o
c
y
te
s
p.N98Tfs25 TNFAIP3/WT
WT/WT
p=<0.0001
0 5 10 20 30 60
60
80
100
120
140
Time (mins)
P
-S
T
A
T
1 
 e
xp
re
ss
io
n
 in
 ly
m
p
h
o
cy
te
s
p.N98Tfs25 TNFAIP3/WT
WT/WT
p=0.0013
D
KJ L
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Supplemental online methods  
Patients 
This study was approved by the Bloomsbury ethics committee (ethics number 08H071382). 
We obtained written informed consent from all the patients, family members and healthy 
controls (ethics number 11/LO/0330) who participated in the study. Baricitinib was made 
available through the following program sponsored by Eli Lilly and Company: 
Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected 
to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and 
Severe Juvenile Dermatomyositis (NCT01724580). 
Genetic sequencing  
Whole exome sequencing (WES) was performed using the Illumina HiSeq 300 platform. 
Data were analysed in Galaxy platform (usegalaxy.org) and SNPs annotated using 
wANNOVAR. The additional case of HA20 studied as disease control, was sequenced on the 
Vasculitis and Inflammation Panel (VIP)(7).  
The TNFAIP3 variant was confirmed and familial segregation ascertained by PCR and 
Sanger sequencing using BigDye v3.1 kit (Applied Biosystems) and primers to amplify and 
sequence exon 8 forward: ATCTCTGTATCGGTGGGGTG and reverse: 
TTGTCACTGTCGGTAGAAAACG.  
 
Peripheral blood mononuclear cell (PBMC) isolation and stimulation 
Peripheral Blood Mononuclear cells (PBMC) were isolated from freshly drawn heparinized 
blood by gradient density centrifugation using LymphoprepTM (StemcellTM Technology, 
Vancouver, Canada). Blood was diluted with the equal volume of RPM1640 medium and 
overlaid on an equal volume of Ficoll-Paque reagent, and then centrifuged 800 g for 10 min. 
The PBMC layer was taken, washed and resuspended in warm RPMI with 10% FCS. Cells 
were seeded at 2×106 cells per well in a 6-well plate and were processed for protein 
extraction or stimulated with 100ng/ml TNFα for up to 60 minutes to induce NF-κB 
activation.  
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Immunoprecipitation and immunoblotting 
Whole cell lysates were prepared using RIPA buffer (Thermo Fisher Scientific) and 1% 
proteinase inhibitor from isolated PBMC or dermal fibroblasts. For immunoprecipitation, 
lysates were mixed with antibodies (1:100) and incubated with 50 µl of protein A Dynabeads 
(Thermo Fisher Scientific) overnight at 4 °C. Immunoprecipitates were boiled in 30 µl of 2× 
Laemmli's buffer with 10% β Mercaptoethanol, washing with PBS. For Immunoblotting, 
samples were subjected to SDS-polyacrylamide gel electrophoresis analysis, and electro 
transferred onto polyvinylidene difluoride membranes (Millipore). Membranes were blocked 
with milk and probed with primary and secondary antibodies and visualized with enhanced 
chemiluminescence detection system (ECL, Amersham Pharmacia Biotech). The following 
antibodies were used: A20/TNFAIP3 (#5630 CST), TBK1 (D1B4, CST), ACTN (MAB 
1501R, MERCK Millipore), RIP1 (#3493, CST), K65-Ub antibody (Merck, 05-1308), Ub 
(sc-271289) and NEMO (sc-56919). 
Caspase-1 activity  
PBMC were seeded in a 96-well plate at a density of 1.6×105 cells/well (8.0×105 cells/ml). 
Relevant wells were primed with 100 ng/ml LPS for 4 h, and, if required, then stimulated 
with 10 mM ATP for 30 min. Caspase-1 activity was measured using FLICA 
(ImmunoChemistry Technologies), a cell-permeable fluorescent probe (FAM-YVAD-FMK) 
that binds active caspase-1. Cells were incubated for 1 h with FLICA at 37°C and stained 
with PE-conjugated anti-CD14 (BD) to identify monocytes. Cells were subsequently 
analyzed for the frequency of CD14+ FLICA+ cells. 
 
Interferon (IFN) stimulated gene RNA expression from whole blood 
Whole blood was collected into PAXgene tubes and RNA extracted using the PreAnalytix 
RNA isolation. RNA concentration was assessed with a Nanodrop (FLUOstar Omega, 
Labtech). We performed quantitative reverse transcription polymerase chain reaction (qPCR) 
analysis using the iTaq Universal SYBR Green Supermix (172-5121, Bio-Rad), and cDNA 
derived from 400 ng total RNA. Using Qiagen Quantitect primers for 
IFI27(NM_001130080), IFI44L(NM_006820), IFIT1 (NM_001001887), 
ISG15(NM_005101), RSAD2(NM_080657), SIGLEC1(NM_023068), the relative abundance 
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of each of these target transcripts were normalized to the expression level of 
HPRT1(NM_000194) (HS_HPRT1_1_SG), assessed using the CFX Maestro software.   
Interferon regulatory factor (IRF-3), Signal transducer and activator of transcription 1 and 3 
(STAT-1, STAT-3) and p65 phosphorylation assays 
PBMC were treated with 100 ng/ml TNF-α for up to 60 min. Cells were fixed using BD Cell 
Fix Buffer (10 min at 37oC) and then permeabilized using BD PermIII Buffer (30min at 4°C) 
prior to staining with PE-anti-NF-κB p65 pS529 (BD Bioscience, cat: 565447), PE-anti- 
IRF3 (BD Bioscience, cat: 612564) PE-anti-STAT1( BD Bioscience, cat: 61256) or Alexa-
fluor-488-STAT3 (BD Bioscience, cat 557814) anrtibodies.  Flow cytometry analysis was 
performed on a BD Calibre flow cytometer. Results were analysed using FlowJo v10.4.2. 
Dermal fibroblasts and siRNA silencing of TNFAIP3 experiments 
Dermal fibroblasts were explanted from III-1 and from controls without any identifiable 
inflammatory condition and maintained in DMEM/F12 (Dulbecco’s Modified Eagle medium: 
Nutrient Mixture F-12) supplemented with 10% FBS and 100U/ml Penicillin and 100µg/ml 
Streptomycin (LifeTechnologies) at 37°C in 5% CO2 in a humidified incubator. siRNA 
knockdown was performed in these fibroblast via transient transfection using with 100 nM of 
siRNA targeting TNFAIP3 (Santa Cruz, SC-37007) or a negative control. siRNAs were 
transfected via complexation with Lipofectamine RNAiMAX (Thermofisher scientific) 
according to the manufacturer’s instructions. At 48 h post transfection knockdown efficiency 
was evaluated by quantitative real-time PCR. The Quantitic TNFAIP3 primers were used 
(Qiagen, QT00070301). 
Measurement of cytokines 
Multiple cytokines were quantified at different time points in the serum of affected patients 
(III-1, III-2 and II-2), family members (II-1), and healthy controls by 
electrochemiluminescence immunoassay using Meso Scale Discovery plates according to the 
manufacturer’s instructions. Data were analysed with Discovery Workbench 4.0. Control sera 
was obtained from healthy paediatric controls (n=15, 9 female median age 14, range 12-18 
years old) with local ethics approval (REC 11/LO/0330). 
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Statistical analyses 
All experiments were complicated in triplicates unless otherwise specified. Results are 
expressed as mean and standard error of the mean or median and range where appropriate. 
All statistics (ANOVA, unpaired Student’s t test, or Mann Whitney U test) and graphs were 
produced using Prism version 7 (GraphPad). P ˂0.05 was considered significant. 
 
Supplemental figure 1. NLRP3 inflammasome activation associated with p.T647P 
heterozygous variant in TNFAIP3. A Peripheral blood mononuclear cells (PBMC) from 
III.1 constitutively expressed higher levels of FLICA (caspase-1) in response to 
lipopolysaccharide (LPS) (mean 16.57, SEM 2.533) compared with controls (mean 4.667, 
SEM 0.01, p=0.009). (B and C). There was increased release of IL-1β  and Il-18 in 
supernatants  from PBMC derived from III.1 following LPS stimulation compared with 
healthy controls (p=0.007 and p=0.01 respectively). Differences in IL-1β, IL-18 secretion and 
caspase 1 activation were also observed between PBMC derived from III.1 and healthy 
control cells after ATP addition. Results are expressed as mean and standard error of the 
mean. P< 0.05 by unpaired t test were considered significant.  NLRP3= NLR Family Pyrin 
Domain Containing 3; TNFAIP3= TNF alpha induced protein 3. 
 
Supplementary figure 2. siRNA mediated silencing of TNFAIP3 enhances type I 
interferon (IFN) signalling. (A-B). Human dermal fibroblasts (HDFC) from III-1 also 
demonstrated increased phosphorylation of STAT1 and STAT3 compared to healthy control 
cells (p=<0.0001 and p=<0.0001 respectively) (C-G) siRNA mediated silencing of TNFAIP3 
in human dermal fibroblast cells (HDFC) resulted in enhanced expression of phosphorylated 
p65((0.04), IRF-3 (p=0.004), STAT-1 (p=0.03), and STAT-3 (p=0.03) compared to 
scrambled siRNA control cells. (G-H) There was increased expression of phosphorylated p65 
in lymphocytes from a patient with p.N98Tfs25 TNFAIP3 variant in comparison to healthy 
control cells (p=0.011). Experiments were performed in triplicate, and results expressed as 
mean and standard error of the mean. P< 0.05 by unpaired t test were considered 
significant.  IRF3=interferon regulatory factor3; STAT1 and STAT3=signal transducer and 
activator of transcription-1 and 3; siRNA= small inhibitory ribonucleic acid; TNFAIP3= TNF 
alpha induced protein 3. 
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Supplementary Table 1:  Patient III-1 routine clinical laboratory investigations. 
Laboratory investigations Patient III.1 (Reference range) 
Autoantibodies persistent >3 months Absent1 
Haemoglobin  10g/L 2 (120-160) 
Platelet count 182x109/L 3 (150-450)  
White blood cell count 6.25 x109/L 4 (4.0-11) 
Lymphocyte subsets Normal  
Immunoglobulin G 19.9 g/L (3.1-13.8) 
Immunoglobulin A 1.94 g/L (0.4-0.7) 
Immunoglobulin M 2.29 g/L (0.5-2.2) 
Immunoglobulin D 7 kU/L (2-100) 
Adenovirus, CMV, EBV, HSV, VZV, 
Parechovirus PCR 
Negative  
Toxoplasma PCR Negative  
Mycoplasma antibodies Negative 
Quantiferon  Negative 
Nitroblue tetrazolium test Normal 
Brucella serology Negative  
Toxocara srology Normal 
16sPCR and 18s PCR CSF 
JC and BK virus 
Negative 
Negative 
Complement C3 1.77 g/L (0.75-1.65) 
Complement C4  0.24 g/L (0.14-0.54) 
Liver enzymes ALT 15 U/L (10 – 25) 
ALP 96 U/L (150-380) 
CSF white cell count 
CSF cytospin 
CSF oligoclonal bands 
< 1x 106 
Negative 
Negative  
 
 
                                                          
1. Autoantibodies tested: antinuclear antibodies, anti-neutrophil cytoplasm antibodies, 
rheumatoid factor, anti-tissue transglutaminase antibodies, anti-thyroid peroxidase antibodies, 
anti myelin oligodendrocyte antibodies, anti-yo, anti-hu, anti ri antibodies, NMDAR 
antibodies, rheumatoid factor antibodies, coeliac screen antibodies, b2 glycoprotein and 
anticardiolipin antibodies.  
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